Enliven Therapeutics (ELVN) Stock: Buy, Sell, or Hold?
ELVN - Enliven Therapeutics, Inc. Common Stock
$54.32
-1.91 (-3.40%)
▼
5d:
-8.94%
30d:
-6.22%
90d:
+34.59%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ELVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ELVN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ELVN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ELVN is currently trading at $54.32, which is considered oversold relative to its 30-day fair value range of $58.25 to $60.44.
Technical Outlook: Technically, ELVN is in a strong uptrend. The price is currently testing key support at $54.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: ELVN scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $73.90 (+36.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELVN is in a strong uptrend. The price is currently testing key support at $54.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: ELVN scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $73.90 (+36.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$58.25 -
$60.44
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding ELVN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (17/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 36.0% below Wall St target ($73.90)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$58.25 -
$60.44
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$54.12
Resistance Level
$61.18
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.23
Wall Street Target
$73.90
(+36.0%)
Share & Embed Analysis
Last updated: September 12, 2026 5:49 AM ET
Data refreshes hourly during market hours. Next update: 6:49 AM
Data refreshes hourly during market hours. Next update: 6:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
Advanced ELVN Option Strategies
Professional options setups generated by AI based on today's ELVN price and gamma walls.
